Bradykinin receptors in GtoPdb v.2023.1

Abstract

Bradykinin (or kinin) receptors (nomenclature as agreed by the NC-IUPHAR subcommittee on Bradykinin (kinin) Receptors [92]) are activated by the endogenous peptides bradykinin (BK), [des-Arg⁹]bradykinin, Lys-BK (kallidin), [des-Arg¹⁰]kallidin, [Phospho-Ser⁶]-Bradykinin, T-kinin (Ile-Ser-BK), [Hyp³]bradykinin and Lys-[Hyp³]-bradykinin. Variation in pharmacology and activity of B₁ and B₂ receptor antagonists at species orthologs has been documented. icatibant (Hoe140, Firazir) is approved in North America and Europe for the treatment of acute attacks of hereditary angioedema. Inhibition of bradykinin with icatibant in COVID-19 infection is under clinical evaluation, with trial NCT05407597 expected to complete in mid 2023.